DICLOFENACO 100 mg TABLETA DE LIBERACION PROLONGADA

Pajjiż: Peru

Lingwa: Spanjol

Sors: DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

Ingredjent attiv:

DICLOFENACO DE SODIO;

Disponibbli minn:

INSTITUTO QUIMIOTERAPICO S.A.

Kodiċi ATC:

M01AB05

INN (Isem Internazzjonali):

DICLOFENAC SODIUM;

Għamla farmaċewtika:

TABLETA DE LIBERACION PROLONGADA

Kompożizzjoni:

POR TABLETA

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

Caja de cartón dúplex x 2, 5, 10, 14, 15, 20, 21, 28, 30, 40, 50, 60, 100, 200, 500 y 1000 Tabletas de Liberación Prolongada en

Tip ta 'preskrizzjoni:

Con receta médica

Manifatturat minn:

INSTITUTO QUIMIOTERAPICO S.A.; PERU

Grupp terapewtiku:

DICLOFENACO

Sommarju tal-prodott:

Presentación: Caja de cartón dúplex x 2, 5, 10, 14, 15, 20, 21, 28, 30, 40, 50, 60, 100, 200, 500 y 1000 Tabletas de Liberación Prolongada en envase blíster de PVC/PVDC ámbar -Aluminio y envase blíster de PVC/PVDC incoloro-Aluminio .

L-istatus ta 'awtorizzazzjoni:

VIGENTE

Data ta 'l-awtorizzazzjoni:

2026-07-04

Karatteristiċi tal-prodott

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Dicloflex Retard 100 mg
Fenactol Retard 100mg
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Diclofenac sodium 100 mg
Excipients(s) with known effect
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Prolonged-release tablet.
Pink, round, biconvex tablet, marked "DICL100" on one face.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
ADULTS AND ELDERLY
Relief of all grades of pain and inflammation in a wide range of
conditions,
including:
(i)
arthritic
conditions:
rheumatoid
arthritis,
osteoarthritis,
ankylosing
spondylitis, acute gout,
(ii)
acute musculo-skeletal disorders such as periarthritis (for example
frozen
shoulder), tendinitis, tenosynovitis, bursitis,
(iii)
other painful conditions resulting from trauma, including fracture,
low
back pain, sprains, strains, dislocations, orthopaedic, dental and
other
minor surgery.
CHILDREN
Diclofenac
Sodium
100mg
prolonged-release
tablets
are
not
suitable
for
children.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
000014
000047
Undesirable effects may be minimised by using the lowest effective
dose for the
shortest duration necessary to control symptoms (see section 4.4).
_ADULTS:_ One 100 mg diclofenac sodium prolonged-release tablet daily.
If necessary,
the daily dosage can be increased to 150 mg by supplementation with
the
conventional dosage forms containing diclofenac sodium 25 mg or 50 mg.
The recommended maximum daily dose of diclofenac sodium is 150mg.
_SPECIAL POPULATIONS _
_ELDERLY:_ Although the pharmacokinetics of Diclofenac sodium are not
impaired to
any clinically relevant extent in elderly patients, nonsteroidal
anti-inflammatory drugs
should be used with particular caution in such patients who generally
are more prone
to adverse reactions. In particular it is recommended that the lowest
effective dosage
be used in frail elderly patients or those with a low body weight (see
also precautions)
and the patient should be monitored for GI bleeding during NSAID
therapy.